Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML

Blood Adv. 2019 Aug 13;3(15):2307-2311. doi: 10.1182/bloodadvances.2019000306.

Authors

Tracy Murphy¹, Jinfeng Zou¹, Georgina S Daher-Reyes¹, Andrea Arruda¹, Vikas Gupta¹, Caroline J McNamara¹, Mark D Minden¹, Aaron D Schimmer¹, Hassan Sibai¹, Karen W L Yee¹, Mariam Korulla^{1

2

3}, Tracy Stockley^{1

2

3}, Suzanne Kamel-Reid^{1

2

3}, Dawn Maze¹, Anne Tierens^{1

2

3}, Scott V Bratman¹, Andre C Schuh¹, Steven M Chan¹

Affiliations

¹ Princess Margaret Cancer Centre and.
² Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; and.
³ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Abstract

DNMT3A^R882, TET2, ASXL1, and SRSF2 mutations identified at the time of diagnosis are associated with delayed count recovery.
Persistence of preleukemic mutations in remission at high variant allele frequency is associated with delayed count recovery.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor*
Blood Cell Count*
High-Throughput Nucleotide Sequencing
Humans
Induction Chemotherapy
Leukemia, Myeloid, Acute / blood*
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / pathology
Mutation*
Prognosis
Retrospective Studies
Treatment Outcome

Substances

Biomarkers, Tumor